奥浦迈将召开临时股东大会，审议增选董事及使用超募资金等议案

Recent Events - The company plans to hold the second extraordinary general meeting of shareholders on February 27, 2026, to review several important proposals, including adjusting the board structure by increasing the number of board members from 7 to 9 and revising the Articles of Association and Board Meeting Rules [1] - The company intends to elect Jifeng Duan as a non-independent director candidate for the second board [1] - The company plans to use 300 million yuan of over-raised funds to permanently supplement working capital, which has been approved by the board and requires shareholder meeting approval [1] Restructuring Progress - The company completed the registration work for the issuance of shares and cash payment for the acquisition of 100% equity of Pengli Bio on February 5, 2026, issuing 16.215872 million shares at a price of 31.57 yuan per share, marking an important step in expanding its business layout [2] Performance and Operations - The company recently released its 2025 annual performance forecast, expecting a net profit attributable to the parent company of approximately 42 million yuan, representing a year-on-year increase of about 99.50%, with investors advised to pay attention to the upcoming audited formal annual report disclosure [3] - The company has revised its Articles of Association and Board Meeting Rules and disclosed an asset impairment loss of approximately 19.1281 million yuan for 2025, primarily related to the low capacity utilization rate of its CDMO biopharmaceutical commercialization production platform [4]